An unexpected incident took place during a White House event featuring U.S. President Donald Trump, where a participant suddenly collapsed, temporarily halting the proceedings.
On the 6th (local time), President Trump made an announcement in the White House Oval Office regarding a significant development involving obesity treatment medications. He stated that Novo Nordisk, the manufacturer of ‘Wegovy,’ and Eli Lilly, the maker of ‘Zepbound,’ had agreed to lower the prices of these treatments in the United States.
President Trump emphasized that both pharmaceutical companies would provide obesity medications to U.S. patients based on the most-favored-nation country standard. He highlighted that the price of Wegovy would drop from $1,350 to $250 per month, while Zepbound’s cost would decrease from $1,080 to $346 per month.
Additionally, he mentioned that Medicare and Medicaid beneficiaries would see their out-of-pocket costs reduced to $50 through government subsidies. This announcement lasted approximately 10 minutes, after which Robert F. Kennedy Jr., the Minister of Health and Welfare, and representatives from the pharmaceutical companies took the podium to speak.
During David Ricks’ remarks as CEO of Eli Lilly, a participant standing behind him suddenly turned pale, swayed, and collapsed. Fortunately, nearby attendees quickly supported him, preventing his head from hitting the ground.
The sudden situation startled not only Ricks, who was speaking, but also President Trump, who stood up from his seat to observe the collapsed attendee. White House staff promptly escorted journalists out of the Oval Office and halted the live broadcast of the event.
According to the UK Independent, the collapsed attendee was identified as Gordon Findlay, an executive at Novo Nordisk. Karoline Leavitt, the White House spokesperson, stated in a press release, “A corporate executive fainted during the most-favored-nation agreement announcement in the Oval Office. The White House medical team responded swiftly, and the man is unharmed. The press conference will resume shortly.”
Once the event restarted, President Trump remarked, “One of the corporate executives collapsed, received medical attention, and is now fine.” The incident served as a brief but notable disruption during what was otherwise a major policy announcement.
Key Details of the Event
- Participants:
- President Donald Trump
- Robert F. Kennedy Jr., Minister of Health and Welfare
- Representatives from Novo Nordisk and Eli Lilly
-
David Ricks, CEO of Eli Lilly
-
Announcements:
- Price reductions for Wegovy and Zepbound
-
Lower out-of-pocket costs for Medicare and Medicaid beneficiaries
-
Incident:
- A Novo Nordisk executive collapsed during the event
- Immediate response from White House medical staff
- Press conference resumed after the incident
Impact of the Announcement
The announcement by President Trump marked a significant shift in how obesity treatments are priced in the U.S. By aligning with the most-favored-nation standard, the administration aimed to make these medications more accessible to a broader population. The price cuts were expected to have a direct impact on patients, especially those relying on Medicare and Medicaid for healthcare coverage.
The event also highlighted the importance of health policy in the current political landscape. With obesity rates continuing to rise, the affordability of medications has become a critical issue for many Americans.
Aftermath of the Incident
Following the collapse, the White House took swift action to ensure the safety of all attendees. The medical team provided immediate assistance, and the individual was reported to be unharmed. The incident underscored the unpredictable nature of public events, even in controlled environments like the White House.
While the event was briefly interrupted, it ultimately resumed, allowing the key messages about medication pricing and accessibility to be conveyed. The focus remained on the policy implications of the agreement between the pharmaceutical companies and the U.S. government.
Conclusion
The White House event, though marred by an unexpected incident, succeeded in delivering important news about the future of obesity treatment in the U.S. The collaboration between the administration and pharmaceutical companies represents a step toward making essential medications more affordable for patients across the country. The incident, while alarming, did not overshadow the significance of the policy announcement, which is expected to have long-term effects on healthcare access and affordability.